Ieq Capital LLC Raises Position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

Ieq Capital LLC raised its holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 825.5% in the 4th quarter, HoldingsChannel.com reports. The institutional investor owned 38,806 shares of the biopharmaceutical company’s stock after acquiring an additional 34,613 shares during the quarter. Ieq Capital LLC’s holdings in Alnylam Pharmaceuticals were worth $9,131,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the business. Venturi Wealth Management LLC boosted its position in Alnylam Pharmaceuticals by 6,200.0% in the 4th quarter. Venturi Wealth Management LLC now owns 252 shares of the biopharmaceutical company’s stock valued at $59,000 after buying an additional 248 shares during the period. Truist Financial Corp boosted its position in Alnylam Pharmaceuticals by 136.6% in the 4th quarter. Truist Financial Corp now owns 4,398 shares of the biopharmaceutical company’s stock valued at $1,035,000 after buying an additional 2,539 shares during the period. CIBC Asset Management Inc boosted its position in Alnylam Pharmaceuticals by 14.5% in the 4th quarter. CIBC Asset Management Inc now owns 5,134 shares of the biopharmaceutical company’s stock valued at $1,208,000 after buying an additional 651 shares during the period. Sanctuary Advisors LLC boosted its position in Alnylam Pharmaceuticals by 7.8% in the 4th quarter. Sanctuary Advisors LLC now owns 4,915 shares of the biopharmaceutical company’s stock valued at $1,157,000 after buying an additional 357 shares during the period. Finally, Capital Performance Advisors LLP boosted its position in Alnylam Pharmaceuticals by 99.3% in the 4th quarter. Capital Performance Advisors LLP now owns 877 shares of the biopharmaceutical company’s stock valued at $206,000 after buying an additional 437 shares during the period. Hedge funds and other institutional investors own 92.97% of the company’s stock.

Analysts Set New Price Targets

Several equities research analysts have recently issued reports on ALNY shares. Chardan Capital reaffirmed a “buy” rating and set a $300.00 price objective on shares of Alnylam Pharmaceuticals in a research report on Friday, November 1st. StockNews.com cut shares of Alnylam Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Thursday, January 9th. Morgan Stanley lifted their price objective on shares of Alnylam Pharmaceuticals from $275.00 to $284.00 and gave the stock an “equal weight” rating in a research report on Friday, February 14th. Sanford C. Bernstein decreased their price objective on shares of Alnylam Pharmaceuticals from $314.00 to $310.00 and set an “outperform” rating for the company in a research report on Tuesday, January 7th. Finally, Royal Bank of Canada reaffirmed an “outperform” rating and set a $300.00 price objective on shares of Alnylam Pharmaceuticals in a research report on Tuesday, February 11th. One investment analyst has rated the stock with a sell rating, six have given a hold rating and nineteen have issued a buy rating to the company’s stock. According to MarketBeat.com, Alnylam Pharmaceuticals currently has a consensus rating of “Moderate Buy” and a consensus target price of $299.48.

Alnylam Pharmaceuticals Stock Performance

Alnylam Pharmaceuticals stock opened at $252.49 on Friday. The firm’s 50 day simple moving average is $254.04 and its 200-day simple moving average is $263.12. The company has a market cap of $32.69 billion, a P/E ratio of -116.36 and a beta of 0.35. The company has a debt-to-equity ratio of 15.27, a current ratio of 2.78 and a quick ratio of 2.71. Alnylam Pharmaceuticals, Inc. has a fifty-two week low of $141.98 and a fifty-two week high of $304.39.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last announced its quarterly earnings data on Thursday, February 13th. The biopharmaceutical company reported ($0.65) EPS for the quarter, missing analysts’ consensus estimates of ($0.62) by ($0.03). As a group, equities research analysts predict that Alnylam Pharmaceuticals, Inc. will post -1.94 EPS for the current year.

Insider Buying and Selling at Alnylam Pharmaceuticals

In other news, EVP Kevin Joseph Fitzgerald sold 1,440 shares of the business’s stock in a transaction on Tuesday, February 18th. The shares were sold at an average price of $251.56, for a total value of $362,246.40. Following the completion of the sale, the executive vice president now directly owns 12,881 shares in the company, valued at approximately $3,240,344.36. The trade was a 10.06 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CMO Pushkal Garg sold 1,548 shares of the company’s stock in a transaction on Tuesday, February 18th. The shares were sold at an average price of $251.67, for a total transaction of $389,585.16. Following the transaction, the chief marketing officer now owns 11,989 shares of the company’s stock, valued at approximately $3,017,271.63. The trade was a 11.44 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 81,356 shares of company stock worth $22,498,551 over the last ninety days. 1.50% of the stock is currently owned by insiders.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.